Different circulating metalloproteinases profiles in women with migraine with and without aura

Clinica Chimica Acta

Volumn 408, Issue 1-2, 2009, Pages 60-64

  Martins Oliveira, Alisson ^a   Speciali, Jose G ^a   Dach, Fabiola ^a   Marcaccini, Andrea M ^a   Gonçalves, Flavia M ^b   Gerlach, Raquel F ^a   Tanus Santos, J E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Metalloproteinases; Migraine; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ZYMOGRAPHY;

ADULT; CASE-CONTROL STUDIES; EPILEPSY; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOPROTEASES; MIGRAINE DISORDERS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 69849106717     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.07.008     Document Type: Article

References (43)

1. Pietrobon D., and Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 4 (2003) 386-398
2. Jensen R., and Stovner L.J. Epidemiology and comorbidity of headache. Lancet Neurol 7 (2008) 354-361
3. Wessman M., Terwindt G.M., Kaunisto M.A., Palotie A., and Ophoff R.A. Migraine: a complex genetic disorder. Lancet Neurol 6 (2007) 521-532
4. Schott G.D. Exploring the visual hallucinations of migraine aura: the tacit contribution of illustration. Brain 130 (2007) 1690-1703
5. Silberstein S.D. Migraine. Lancet 363 (2004) 381-391
6. Welch K.M. Contemporary concepts of migraine pathogenesis. Neurology 61 (2003) S2-8
7. Sanchez-del-Rio M., and Reuter U. Migraine aura: new information on underlying mechanisms. Curr Opin Neurol 17 (2004) 289-293
8. Waeber C., and Moskowitz M.A. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology 61 (2003) S9-20
9. Goadsby P.J. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13 (2007) 39-44
10. Peroutka S.J. Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 5 (2005) 304-311
11. Williamson D.J., and Hargreaves R.J. Neurogenic inflammation in the context of migraine. Microsc Res Tech 53 (2001) 167-178
12. Hu J., Van den Steen P.E., Sang Q.X., and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6 (2007) 480-498
13. Leppert D., Lindberg R.L., Kappos L., and Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 36 (2001) 249-257
14. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., and Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122 (1999) 191-197
15. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., and Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21 (1998) 75-80
16. Gurney K.J., Estrada E.Y., and Rosenberg G.A. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23 (2006) 87-96
17. Rosenberg G.A., Cunningham L.A., Wallace J., et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 893 (2001) 104-112
18. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 39 (2002) 279-291
19. Edvinsson L., and Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia 22 (2008) 22
20. Gursoy-Ozdemir Y., Qiu J., Matsuoka N., et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113 (2004) 1447-1455
21. Imamura K., Takeshima T., Fusayasu E., and Nakashima K. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 48 (2008) 135-139
22. Leira R., Sobrino T., Rodriguez-Yanez M., Blanco M., Arias S., and Castillo J. Mmp-9 immunoreactivity in acute migraine. Headache 47 (2007) 698-702
23. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
24. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., and Marmer B.L. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267 (1992) 4583-4591
25. Palei A.C., Sandrim V.C., Cavalli R.C., and Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 41 (2008) 875-880
26. Souza-Costa D.C., Sandrim V.C., Lopes L.F., Gerlach R.F., Rego E.M., and Tanus-Santos J.E. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis 193 (2007) 438-444
27. The International Classification of Headache Disorders. 2nd ed. Cephalalgia vol. 24 Suppl 1 (2004) 9-160
28. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 344 (2005) 147-149
29. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 40 (2007) 119-123
30. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38 (2005) 410-414
31. Castro M.M., Rizzi E., Figueiredo-Lopes L., et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198 (2008) 320-331
32. Makowski G.S., and ML. R. Identification and partial characterization of three calcium- and zinc-independent gelatinases constitutively present in human circulation. Biochem Mol Biol Int 46 (1998) 1043-1053
33. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
34. Martinez M.L., Castro M.M., Rizzi E., et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 591 (2008) 224-230
35. Kurth T., Gaziano J.M., Cook N.R., Logroscino G., Diener H.C., and Buring J.E. Migraine and risk of cardiovascular disease in women. JAMA 296 (2006) 283-291
36. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 (1999) 906-911
37. Fernandez-Patron C., Stewart K.G., Zhang Y., Koivunen E., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 (2000) 670-676
38. Martinez A., Oh H.R., Unsworth E.J., et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383 (2004) 413-418
39. Souza-Costa D.C., Figueiredo-Lopes L., Alves-Filho J.C., et al. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 35 (2007) 239-245
40. Martinez M.L., Lopes L.F., Coelho E.B., et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47 (2006) 117-122
41. Fortuna G.M., Figueiredo-Lopes L., Dias-Junior C.A., Gerlach R.F., and Tanus-Santos J.E. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 114 (2007) 22-27
42. Rosenberg G.A., Estrada E.Y., Dencoff J.E., Mun-Bryce S., and Rosenberg G.A. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Matrix metalloproteinases in cerebrovascular disease. Stroke 29 (1998) 2189-2195
43. Eye Y.Y., Thompson J.F., Liu W., and Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27 (2007) 697-709